Chabanon et al., 2020 - Google Patents
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancersChabanon et al., 2020
- Document ID
- 13205818579998846278
- Author
- Chabanon R
- Morel D
- Postel-Vinay S
- Publication year
- Publication venue
- Seminars in Cancer Biology
External Links
Snippet
Mammalian switch/sucrose non-fermentable (mSWI/SNF) family complexes are pivotal elements of the chromatin remodeling machinery, which contribute to the regulation of several major cellular functions. Large-scale exome-wide sequencing studies have …
- 201000011510 cancer 0 title abstract description 89
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chabanon et al. | Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers | |
| Jia et al. | Super-enhancers: critical roles and therapeutic targets in hematologic malignancies | |
| Wen et al. | Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway | |
| Marazzi et al. | Chromatin dependencies in cancer and inflammation | |
| Frühwald et al. | Atypical teratoid/rhabdoid tumors—current concepts, advances in biology, and potential future therapies | |
| Hamilton et al. | Targeting CDK4/6 in patients with cancer | |
| Scott et al. | Nucleolin and nucleophosmin: nucleolar proteins with multiple functions in DNA repair | |
| US10071129B2 (en) | Method for identifying bromodomain inhibitors | |
| Bronte et al. | The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? | |
| Greenaway et al. | Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer | |
| Tsigelny et al. | Molecular mechanisms of OLIG2 transcription factor in brain cancer | |
| Yi et al. | Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma | |
| Rosich et al. | Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma | |
| Chu et al. | Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer | |
| Blokken et al. | Protein–protein and protein–chromatin interactions of LEDGF/p75 as novel drug targets | |
| Węsierska-Gądek et al. | PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells | |
| Girardini et al. | Disarming mutant p53 oncogenic function | |
| Gorjánácz | Nuclear assembly as a target for anti-cancer therapies | |
| Moia et al. | Targeting p53 in chronic lymphocytic leukemia | |
| Du et al. | The absence of PTEN in breast cancer is a driver of MLN4924 resistance | |
| D'costa et al. | CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells | |
| Rose et al. | The role of inner nuclear membrane proteins in tumourigenesis and as potential targets for cancer therapy | |
| Forgione et al. | MLLT10 rearranged acute leukemia: incidence, prognosis, and possible therapeutic strategies | |
| Foroutan | A Narrative Review of the TP53 and Its Product the p53 Protein | |
| Nahta et al. | Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer |